Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

NextFerm Technologies announces a strategic manufacturing agreement for the production of ProteVin™, its vegan protein, with a subcontractor in Europe

NextFerm Technologies Ltd.

The commissioning of the plant will be completed in the second half of 2023 with an annual production capacity of about $10M, with future expansion capacity to tens of millions of dollars per year The subcontractor will bear the costs of constructing the plant’s building and will provide all infrastructure and production services as well as the baker’s yeast necessary to produce ProteVin™. The company will bear the costs of purchasing and installing the equipment necessary for production The product was launched to several customers and the company has a wide range of food and dietary supplement companies including global companies, who are examining the integration of ProteVin™ in a variety of alternative products (Yokneam Illit, September 8, 2022) – NextFerm Technologies Ltd. (TASE:NXFR), a food-tech company developing ProteVin™, a vegan, fermentation-based, non-GMO protein alternative and other innovative yeast-based nutrients, announced today a strategic manufacturing agreement for the production of ProteVin™ with a subcontractor in the Balkan region in Europe. This marks the achievement of the company’s third strategic milestone (out of five) set for 2022. According to the agreement, the manufacturing plant will enable, at first stage, the production of ProteVin™ with an annual capacity of up to $10M starting the second half of 2023. The plant commissioning plan enables a future expansion of the capacity to tens millions of dollars. This plant is expected to replace the current pilot production plant in GFR Canada. The subcontractor will establish the plant and will provide the production services as well as the baker’s yeast necessary to produce ProteVin™. The company will bear the costs of purchasing and installing the equipment necessary for production. The Company estimates that the necessary investment needed for the completion of the manufacturing plant and reaching the above mentioned capacity will be approximately $6M. The main equipment needed for the plant was already ordered. The agreement relates only for production services and doesn’t include IP transfer to the subcontractor. Boaz Noy, Chief Executive Officer of NextFerm, said: "This manufacturing agreement for the production of our vegan protein is an important milestone for our Company and represents the transition into an industrial company in the field of alternative proteins. The plant was designed in a way that would allow investment in the production capacity in accordance with the increase in demands. ProteVin™ is the only alternative protein on the market today with a neutral taste and an animal-like nutritional value, and we believe it will become a leading solution in the global alternative protein industry.” About NextFerm Technologies NextFerm Technologies, traded on the Tel Aviv Stock Exchange (TASE:NXFR) is a food-tech company engaged in the research, development, manufacturing and marketing of innovative, functional and vegan yeast-derived, non-GMO protein alternatives for various applications in the food and food supplement markets and the growing market for animal-derived protein alternatives. NextFerm's flagship product is ProteVin™, a vegan, yeast-derived protein with animal-like nutritional value (Amino acid profile BCAA=21%, Leucine=9%, EAA=53% and high digestibility PDCAAS=1) and a neutral flavor. ProteVin™ is designed for a variety of categories in the alternative protein market, which is estimated at USD 20 billion in terms of final products and at USD 3.5 billion in terms of raw materials with an annual growth rate of above 20%, including milk and dairy substitutes, meat substitutes and additional categories such as infant nutrition, adult nutrition, and sports nutrition. Another product currently being sold is Astaferm®, an innovative astaxanthin-based antioxidant derived from yeast that has been sold in the US since the end of 2020 through well-established and leading brands in the food supplement market in the US. In July 2021, the Company received Regulatory marketing approval in Canada. The company has additional products which have been licensed to Lallemand, a global giant focused on yeast. For more information, visit the NextFerm website at: www.nextferm.com Legal Notice Regarding Forward-Looking Statements This announcement also includes forecasts, projections, assessments, estimates and other information which refer to future events and matters, the realization of which is uncertain and not exclusively under the Company’s control (forward-looking information). The main facts and data used to support this information are facts and data regarding the current position of the Company and its businesses (including the scope of sales and levels of profitability, manpower, commercial engagements and more), facts and data regarding the current global position of the Company’s operating segments (including industry-specific financial developments, environmental regulatory developments, the competitive environment, technological developments, the reinsurance market and more), and macro-economic facts and data (including the economic situation both in Israel and around the world, yields in the capital markets, social and state developments and more), all as known by the Company when publishing this announcement. The forward-looking information included above in this announcement is significantly based upon, in addition to the existing information held by the Company, on the Company’s current assessments and expectations of future developments vis-a-vis each one of the aforementioned parameters, and the interconnectedness of each one of these developments. The Company has no certainty that its forecasts and assessments will indeed eventuate, and the Company’s operating results may be materially different than the results assessed or implicit based on that set forth above, inter alia, as a result of a change in any of the aforementioned factors. Contact Details Investor and Media Contact Meirav Gomeh-Bauer +972 54-476-4979 meirav@bauerg.com Company Website https://www.nextferm.com/

September 08, 2022 09:00 AM Eastern Daylight Time

Biocidin Botanicals™ Launches Dentalcidin® Oral Care System, the First Dentaceutical™ Solution for Oral Microbiome Health

Biocidin Botanicals

Biocidin Botanicals ™, a pioneer in botanical supplements and microbiome health, announced today the launch of its two-step Dentalcidin ® Oral Care System. The system consists of the company’s reformulated and repackaged Dentalcidin® Oral Microbiome Toothpaste along with its Dentalcidin® LS Liposomal Rinse. Combining the toothpaste and oral rinse into a two-step system ensures comprehensive health benefits for customers. It also recognizes the science-backed connection between the oral microbiome and whole-body health. ( Learn more ) “We’re excited to take what we’ve learned over the past 30-plus years about microbiome health and apply it to the things we use every day, like toothpaste and mouth rinse,” said Rachel Fresco, L.Ac., Ph.D., Biocidin Botanicals’ Founder and Formulator. “Research continues to confirm that whole-body health starts in the mouth. These products are more than just toothpaste and mouthwash. We’ve coined a new term for it. They’re “Dentaceuticals ™” – natural dental formulations that improve the health of teeth and gums and ultimately support whole-body wellness. When used together, these products provide incredible health support!” Dentalcidin Oral Microbiome Toothpaste® has been available for several years. In response to customer feedback and keeping with the company’s sustainability goals, Biocidin Botanicals reformulated and repackaged the toothpaste this year, a decision that reflects its commitment to both people and planet. “As a company, we believe our choices matter,” Fresco said. “We care about our customers and listen to them. We also constantly evaluate our impact on the planet. That’s why we made the decision to reformulate the toothpaste to be 100% plant-based and to deliver it in a sleek, stand-up tube that is 100% recyclable. It’s easier to use and easier on the planet.” Both products in the Dentalcidin® Oral Care System are powered by the 18 botanical extracts and essential oils in Biocidin®, the company’s broad-spectrum, legacy formula. This clinically effective, evidence-based proprietary blend has been trusted by health professionals for over 32 years. Great Smokies Diagnostic Laboratories (now Genova Diagnostics) called it one of the most potent natural formulations they’ve ever analyzed. With other select botanicals providing added synergy and benefits, the entire system relies on a 100% natural, plant-based, and chemical-free ingredient list to give practitioners and consumers robust health benefits derived from the best botanical sources. The Dentalcidin® Oral Care System delivers the results usually associated with toothpaste and an oral rinse. It whitens teeth, freshens breath, and is gentle enough for sensitive teeth. But thanks to Biocidin Botanicals’ commitment to putting “Serious Science Behind Every Smile™,” its benefits go far beyond. Comprehensive university research, case studies, rigorous testing, and innovative formulation processes have resulted in a system with unique health benefits. The Dentalcidin® Oral Care System: Assists in removing oral biofilms (plaque) Utilizes liposomal technology for deeper penetration in the periodontal area* Supports gum and gingival health with targeted ingredients such as CoQ10, quercetin, clove, and myrrh* Provides tissue-soothing activity* Supports oral microbiome balance for whole-body health* Keeps teeth feeling clean and smooth all-day “This system really demonstrates the power of botanicals to support a balanced oral microbiome,” Fresco said. “Because oral health directly impacts systemic health, a balanced oral microbiome also supports whole-body health, including cognitive, respiratory, cardiovascular, gastrointestinal, and joint health. But the reverse is also true. Poor oral health impacts more than just your mouth. That motivated us to develop something uniquely powerful, an innovative Dentaceutical solution.” Dentists, dental hygienists, and integrative and functional practitioners recommend Dentalcidin® toothpaste and oral rinse. Functional dentist Dr. Ariana Ebrahimian says of the products, “I highly recommend Biocidin Botanicals’ oral care products to my patients and use the liposomal rinse in our scaling procedures. They are incredibly effective at busting up harmful biofilms in the mouth and rebalancing the oral microbiome without the harsh side effects of chemicals.” The launch of Biocidin Botanicals’ Dentalcidin™ Oral Care System is a true breakthrough in oral care, bolstering the company’s position as a thought leader and innovator in the botanical supplements space. ABOUT BIOCIDIN BOTANICALS ™ Biocidin Botanicals™ is a leader in botanical supplements and a pioneer in microbiome health. Its legacy broad-spectrum botanical blend Biocidin® was formulated in 1989 in response to challenging health conditions related to microbial imbalances. More than 30 years later, the company offers a curated line of targeted support products to boost patient health. Healthcare practitioners have utilized these clinically effective, evidence-based products for over three decades to help millions of patients achieve vibrant health and wellness. Biocidin Botanicals™ will continue to lead the way in functional and integrative medicine through its plant-powered products. Visit their website at www.biocidin.com or check them out on Instagram or LinkedIn for more information. Contact Details Biocidin Botanicals Susan Fecko +1 307-690-8381 sfecko@blackdogstudiopr.com Company Website https://biocidin.com/

September 08, 2022 08:30 AM Eastern Daylight Time

Image

Introducing the GE Safety Helmet with patented technology by Caco America LLC

Caco Abbo Internacional

Caco America LLC a subsidiary of Caco Abbo International, S.A., leader for more than 36 years in the PPE market with sales in more than 35 countries and the exclusive licensee of GE, for the design, manufacturing, and distribution of GE branded personal protective equipment (“PPE”) products for the Americas, is pleased to announce the launch of the GH400 safety helmet with a patented technology at the next NSC show September 2022 in San Diego, CA. Booth 2131. Caco America LLC is committed in bringing the best technologies and designs to the workforce to improve the occupational safety, health, and well-being of workers. The Future of the safety helmet has arrived with the GE branded, safety helmet (part number GH400). In partnership with Koroyd™ Technologies, Caco America has designed one of the lighter, smaller, and more breathable helmets in the industry. The GH400 protective helmet is engineered with the patented Koroyd™ impact-absorbing technology. Its cross-ventilation cooling feature and light weight provide the user with the most comfortable fit in the market. It facilitates the job through an array of accessories available and gives the user a better-looking style due to its lower profile design. Available vented or non-vented. Type 1, Class C, and Class E. Please see the complete GH400 protective helmet brochure here. At the trade show, Caco America will also be presenting the GG244-FUSEFLEX gloves with a patent pending TPR design that has an A5 cut resistant feature as well as an IMPACT 2 protection. The GG244 FUSEFLEX is a foam nitrile patent pending TPR Impact Glove. This glove has the latest in engineering TPR protection to provide flexibility, comfort, and protection all day long. The 18-gauge liner was developed to feel light and thin while providing ANSI cut level 5 protection (A5) due to the components of its fibers. Its black foam nitrile palm coating provides outstanding dexterity, enhanced grip, and touchscreen compatibility. For even more protection, it has a longer cuff and a stitched reinforced crotch thumb. Please see our complete catalog here. About Caco Abbo Caco Abbo Internacional, S.A. was founded in 1986 by Mr Isaac Abbo V and his son Jose M Abbo. In 1992 Joel Abbo joined the company and expanded the development of products and international sales. Today, Caco Abbo International, S.A. is one of the top Import/Export Companies in the Americas with sales in more than 35 countries. www.cacoamerica.com About GE GE (NYSE:GE) rises to the challenge of building a world that works. For more than 125 years, GE has invented the future of industry, and today the company's dedicated team, leading technology, and global reach and capabilities help the world work more efficiently, reliably, and safely. GE's people are diverse and dedicated, operating with the highest level of integrity and focus to fulfill GE's mission and deliver for its customers. www.ge.com Contact Details Caco America LLC Isaac Joel Abbo +1 305-512-1150 sales@cacoamerica.com Company Website https://www.geppe.cacoamerica.com/

September 07, 2022 12:46 PM Eastern Daylight Time

Image

Local Lab Campaigns for Science-Backed Cannabis Policies, Business Practices

MCR Labs

Local cannabis testing and research laboratory MCR Labs will be leading open discussions on how to better inform cannabis policies, legislature, and cultivation through the use of data and science. As one of the first independent cannabis testing labs to be established in Massachusetts with the largest cannabis data set on the east coast, MCR Labs is uniquely positioned to guide these conversations. MCR Labs will host several events centered around sensible policy-making and industry standards. The campaign will culminate with MCR’s annual Cannabis Science Fair, showcasing the latest exciting cannabis research and innovation. “What we really need to get away from, especially on a legislative level, is allowing special interests and long-time stigmas to get in the way of sensible policy-making that protects consumers and patients,” said MCR Founder Michael Kahn. “It’s time objective data derived from sound science is used to inform this industry.” The campaign, titled “Science Over Stigma,” is sponsored by Boston Cannabis Week, an organization that curates a week of events for cannabis professionals, consumers and industry innovators. Set in September, Boston Cannabis Week will feature Science Over Stigma’s kick-off event “Cannabis Through the Ages” on Monday, September 19. Learn more about the campaign and upcoming events here. About MCR Labs: MCR Labs is one of the longest operational cannabis testing laboratories on the East coast with facilities operating in several legal cannabis markets. We are ISO/IEC 17025:2017 accredited providers of analytical cannabis product testing and R&D services committed to assisting licensed marijuana establishments, patients, researchers, entrepreneurs, and advocates. Our team of chemists and pharmaceutical scientists are dedicated to advancing public health and safety through leading-edge chemical analysis of cannabis products and offering unparalleled guidance and support for partners, regulators, and the communities we serve. For more information visit http://mcrlabs.com. Contact Details Alexandra Gomes +1 508-782-9772 alexandra@mcrlabs.com Company Website http://mcrlabs.com

September 07, 2022 08:00 AM Eastern Daylight Time

Image

AliMed, Inc. awarded Pediatric Straps and Positioners agreement with Premier, Inc.

AliMed, Inc.

AliMed, Inc., a Massachusetts-based medical supply manufacturer and distributor, has been awarded a national group purchasing agreement for pediatric straps and positioners with Premier, Inc., and their Performance Group, Kiindo™. Effective June 1, 2022, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for pediatric straps and positioners. “AliMed is committed to serving the pediatric community with high-quality healthcare products designed specifically for their needs,” said Adrienne Hamilton, Director of Marketing at AliMed. “We are excited about this agreement and look forward to working with Premier members to help them realize cost savings, improve efficiencies, and support better quality outcomes across the pediatric continuum of care.” With many products tailored to the unique needs of children from neonatal to adolescents, the AliMed contract includes imaging and surgical straps that provide support and stabilization without damaging delicate pediatric skin, surgical positioners appropriately sized to help relieve pressure from head to foot during procedures, and rehab positioners that aid with strengthening motor skills, balance, mobility, feeding, and more. Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,400 U.S. hospitals and 250,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting, and other services, Premier enables better care and outcomes at a lower cost. About AliMed AliMed, Inc. manufactures and distributes acute and post-acute medical products and devices. For over 50 years, AliMed has innovated to deliver flexible supply chain solutions with superior service and value-based products focused on the safety and productivity of the healthcare community. AliMed’s broad portfolio of products for domestic and international care providers, dealers, and distributors are designed to improve patient outcomes and experiences from “hospital to home.” Contact Details Katie McKinley, Sr. Marketing Product Manager, ORMI 781-329-2900 x 214 kmckinley@alimed.com

September 06, 2022 09:00 AM Eastern Daylight Time

Image

It All Comes Down To Science And Research With The Efficacy Of Jupiter Wellness’s Lineup Of Skin And Hair Treatment Drugs

Jupiter Wellness, Inc.

Today’s consumers are seemingly more health and wellness conscious than ever before. With the increase in social media use, there is even more emphasis placed on personal appearance, with both men and women upping their wellness game be it in skin care, hair care, general health, and wellbeing, or attempting to preserve youthfulness. Jupiter Wellness Inc. (NASDAQ: JUPW), which focuses on making drugs and skin- and hair-care products, is riding on this emerging trend. The company reports that it’s changed its focus and sharpened its vision over the last year in its journey to rebrand itself and transform into a science- and research-backed pharmaceutical company that uses its health-sciences division for the production, testing, and sale of products aimed at the skin, hair and sexual wellness as well as general health. Jupiter‘s development pipeline includes products to address psoriasis, eczema, burns, herpes and cold sores, hair loss and female libido loss. In fact, last year, the company put its money where its mouth is by acquiring certain assets of Applied Biology, a biotech company specializing in skin and hair science that provides clinical research for several of Jupiter Wellness’s proprietary dermatological treatment products. A Diverse Lineup Of Products Jupiter’s top-of-the-line product is its JW-100, which the company says is a novel topical formulation containing CBD and aspartame used for the topical treatment of atopic dermatitis (eczema) and is in direct competition with Pfizer Inc. ’s (NYSE: PFE) Eucrisa. The company is conducting a Phase 3, double-blind, placebo-controlled multicenter trial to evaluate the superiority of JW-100 to Eucrisa (a Food and Drug Administration (FDA)-approved topical drug) in mild-to-moderate eczema, and it is optimistic that JW-100 may prove superior to Eucrisa and other comparable prescription drugs on the market. Market analysis and go-to-market plans are being developed with an anticipated product launch in 2023, according to the company. Another product in Jupiter's development pipeline is RJ-101, a topical treatment for female libido loss that was discovered when the drug was being used to treat breast cancer and chemotherapy patients who reported an increase in sexual desire as an unexpected side effect. Jupiter has continued clinical trials and reports that RJ-101 increased nipple erection, sensitivity, and genital lubrication in healthy patients as well as those with nipple neuropathy. Jupiter plans to launch RJ-101 in 2023, this product may go both the FDA route as a prescription drug or as a consumer product for female libido loss and potentially as a product for general sexual wellness and pleasure for women. Jupiter’s Minoxidil Booster is an over-the-counter drug used to treat of hair loss. It reportedly works by enriching the sulfotransferase enzyme in the hair and amping up the efficacy of Minoxidil for hair loss. Jupiter says it has licensed its Minoxidil Booster to Taisho, a $2.6 billion Japanese company that is the leading seller of minoxidil products in Japan. Taisho expects to launch the product commercially in 2023. The company’s other skin-care products include Photocil, a topical treatment for psoriasis and vitiligo; JW-300, a topical used to treat first-degree burns and sun exposure; JW 400, a product for treating herpes labialis (cold sores); and NoStingz, a unique sunscreen that protects the skin from jellyfish stings, sea lice, and UVA/UVB rays. NoStingz has been available since April through Amazon.com Inc. (NASDAQ: AMZN), Walmart Inc. (NYSE: WMT), and other select stores with sales growing steadily month over month, according to the company. The company reported revenue of $3.7 million in the first half of 2022. “I am pleased to report that Jupiter Wellness is on track with its 2022 roadmap,” Jupiter Wellness CEO Brian John said. “Jupiter finished the first half of 2022 with momentum and our strongest revenue numbers to date”. Learn more about Jupiter Wellness here. We support health and wellness through the research and development of over-the-counter (OTC) products and intellectual property. Our product pipeline addresses a range of conditions, including hair loss, eczema, burns, and sexual wellness. Revenue is generated through the sales of OTC and consumer products, contract research agreements, and licensing royalties. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR- Camille Baptiste camille@tradigitalir.com Company Website https://jupiterwellness.com/

September 06, 2022 08:55 AM Eastern Daylight Time

Communication Service for the Deaf Names Jessica Kennedy the New President of CSD Health

Communication Service for the Deaf

As September’s Deaf Awareness Month celebrations begin, Communication Service for the Deaf (CSD) is happy to announce that Jessica Kennedy has been named the new President of CSD Health. Kennedy has previously served as CSD’s Vice President of Legal and Compliance. The new CSD health division will be the home of all the organization’s health care initiatives, with a focus on ensuring that there is equitable healthcare access for Deaf, DeafBlind, DeafDisabled, hard-of-hearing, and late-deafened people whose daily lives are impacted by barriers to accessible communications options within the healthcare system. One of the fundamental rights belonging to every human being is access to medical care. Yet, even within the United States, deaf communities are often not afforded this dignity. Changes must be made. CSD is prioritizing the healthcare space as a top issue for advocacy and change. “We believe Jessica is the perfect person to lead our work to achieve truly accessible and equitable healthcare experiences and outcomes for our community,” said Chris Soukup, CEO of CSD. “This division will confront the challenges within the healthcare system head-on and advocate for real and lasting change.” The current system is full of barriers that deaf communities must navigate daily. Users of American Sign Language (ASL) are at a higher risk for poor health knowledge and inequitable access to medical and behavioral care in our current health system due to cultural and language barriers. For example, miscommunication when using a third-party interpreter can result in more than simple frustration-- it jeopardizes primary care. Because of this, deaf communities often have significant health disparities and are often excluded from health outreach programs and mass media healthcare messages. Deaf patients can embody a unique culture that is unfamiliar to most medical and mental healthcare providers. This lack of cultural and linguistic competency often results in higher rates of inaccurate evaluations, misdiagnoses, and inappropriate treatments. To answer these concerns, Kennedy envisions the health division advocating for equitable and accessible health reform efforts, promoting innovative and transformative ideas to strengthen health care for deaf communities, bridging access in federal and state public health emergencies, and working towards culturally responsive medical providers for our communities. “Healthcare access is critical,” Kennedy signed in ASL. “Good health is a human need that binds all humanity together. When it is not accessible, or groups get left behind, that separates us as a global community. We must and will do better." About Communication Service for the Deaf Communication Service for the Deaf (CSD) is the world's largest Deaf-led social impact organization. For more than four decades, CSD has been a leader in creating and providing accessible and innovative solutions for the Deaf community. Today, CSD continues its work to create opportunities for personal and economic growth within the Deaf community, explicitly addressing leadership and employment. For more information, please visit CSD and follow us on Facebook, Twitter, Instagram, and LinkedIn. About Jessica Kennedy Jessica Kennedy is an attorney and disability rights advocate. As the Vice President of Legal and Compliance for Communication Service for the Deaf, Inc. (CSD), Ms. Kennedy proudly served as part of a team dedicated to empowering people with disabilities. Previously, she was the Deputy General Counsel and Policy Director at MNsure, contributing to the implementation and overhaul of Minnesota’s health insurance exchange and the dynamic policy landscape that followed. Prior to MNsure, Ms. Kennedy served as an in-house attorney for the Minnesota Department of Human Services, advising on healthcare and privacy issues. She received her B.A in political science from the University of Minnesota and her J.D. from Mitchell Hamline School of Law in St. Paul. Ms. Kennedy currently serves as a board member of the Deaf and Hard of Hearing Bar Association and MNsure, as a board member representing consumers eligible for public health care program coverage. Media Contact: Waymon Hudson media@csd.org About Communication Service for the Deaf Communication Service for the Deaf (CSD) is the largest Deaf-led social impact organization in the world. For more than four decades, CSD has been a leader in creating and providing accessible and innovative solutions for the Deaf community. Today, CSD continues its work to create opportunities for personal and economic growth within the Deaf community, specifically addressing leadership and employment. For more information, please visit CSD and follow us on Facebook, Twitter, Instagram, and LinkedIn. Contact Details Communication Service for the Deaf Waymon Hudson media@csd.org Company Website https://www.csd.org/

September 01, 2022 11:00 AM Central Daylight Time

Image

Is Growing Awareness Of Good Oral Hygiene Driving Growth Of Electric Toothbrush Market?

Bruush Oral Care Inc.

Learn More about Bruush Oral Care Inc., by gaining access to the latest research report. The debate over whether electric or manual toothbrushes do a better job of cleaning your teeth has raged for decades. While both manual and electric toothbrushes are effective at removing plaque, powered toothbrushes often are easier for people who have dexterity issues, such as the elderly, people with disabilities or children, according to the American Dental Association (ADA). The Journal of the American Dental Association published a survey that found that 13,000 out of 16,000 patients who used an electric toothbrush reported better oral health. Still, only 36% of adults say they use an electric toothbrush, according to a report by consumer marketing analysis firm Mintel. The global electric toothbrush market size was estimated to be worth $4.3 billion in 2022 and projected to increase to just over $6 billion by 2027, according to Statista. The market is being driven by the prevalence of periodontal diseases and heightened awareness of the advantages of electric toothbrushes. Electric toothbrush bristles vibrate or rotate to remove plaque buildup from teeth and gums. There are pros and cons to an electric toothbrush. On the plus side, they’re easy to use; most have timers so users can tell whether they’ve brushed their teeth for the full two minutes dentists recommend, and some people feel that their teeth are cleaner. “If you choose an electric toothbrush, make sure the toothbrush is comfortable to hold and easy to use,” said Thomas Salinas, a prosthodontist with the Mayo Clinic in Rochester, Minnesota. “Whether you choose an electric toothbrush or a manual toothbrush, remember that what’s most important is daily brushing and flossing.” Electric toothbrushes also may generate less waste. The ADA recommends replacing your toothbrush every three months, and with an electric toothbrush, you’re just replacing the brush head — not the entire device as you would with the manual version. What Are The Drawbacks? However, electric toothbrushes are more expensive than their manual counterparts; they require charging, and they’re difficult to travel with. And replacing brush heads can be expensive. Replacement brush heads for Sonicare can cost as much as $43 for a three-pack, and the price of Oral-B line of brush heads reaches as high as $40 for a three-pack, depending on the model. What Is A Solution? An example of a more affordable alternative is the Brüush (NASDAQ: BRSH) electric toothbrush, which comes in five colors. Like Blue Apron Holdings Inc. (NYSE: APRN) and Stitch Fix Inc. (NASDAQ: SFIX), which send their food and clothing products to customers who sign up, Brüush’s subscription model makes it easy for consumers to stay on top of replacing their brush heads every three months as dentists recommend. If you sign up for a subscription, Brüush will send you three new brush heads every six months for $18 — just $6 per brush head. The Brüush toothbrush has six cleaning modes for every type of brusher — daily, white, gentle, gum, max, and tongue. Brüush’s electric toothbrush kit sells for $79 and includes the electric toothbrush, three brush heads, and a USB power adapter and charger. The Brüush lithium-ion battery lasts for four weeks on a single charge, and the compact magnetic case makes traveling with the device convenient. Visit Brüush’s website to learn more about the company and its products. About Bruush Oral Care Inc. Bruush Oral Care Inc. is on a mission to inspire confidence through brighter smiles and better oral health. Founded in 2018, Brüush is an oral care company that is disrupting the space by reducing the barriers between consumers and access to premium oral care products. The Company is an e-commerce business with a product portfolio that currently consists of a sonic-powered electric toothbrush kit and brush head refills. Brüush has developed a product to make upgrading to an electric brush appealing with three core priorities in mind: (i) a high-quality electric toothbrush at a more affordable price than a comparable electric toothbrush from the competition; (ii) a sleek, countertop-friendly design; and (iii) a convenient brush head refill subscription program that eliminates the frustrating experience of purchasing replacement brush heads at the grocery/drug store. The Company is rooted in building a brand that creates relevant experiences and content, with the goal of becoming the go-to oral care brand for millennials and Generation Z.For more information on Bruush Oral Care Inc visit https://bruush.com. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR - Colette Eymontt colette@tradigitalir.com Company Website http://www.tradigitalir.com

September 01, 2022 09:15 AM Eastern Daylight Time

Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst

BioRestorative Therapies, Inc.

In 2016, Americans spent roughly $380 billion on lower back and neck pain. In the same year, medical costs for adult obesity in the United States were $260.6 billion. That’s why BioRestorative Therapies Inc. (NASDAQ: BRTX) is working to develop treatments for these 2 indications, laser-focusing on obesity and lower back pain. Lower back pain and obesity are major health crises. Lower back pain is the leading cause of disability worldwide, and obesity has been identified as a national security threat by the Department of Defense. With the escalation of both lower back pain and obesity in recent years, companies have realized the market potential for finding ways to improve the lives of those suffering from these conditions. Companies such as Pfizer Inc. (NYSE: PFE), Novo Nordisk (NYSE: NVO) and Vertex Inc.. (NASDAQ: VRTX) seem to have recognized the market potential for potential obesity treatments and are actively looking for the next breakthrough in obesity therapies. FDA Authorizes BioRestorative to Begin Phase 2 Clinical Trials For Chronic Lower Back Pain Indication; Development For Brown Fat Indication Underway BioRestorative Therapies is looking into the viability of BRTX-100 as an alternative to current treatments for chronic lower back pain that manages the pain rather than attacking the root cause such as pain relievers, steroid injections and opioids. The Food and Drug Administration (FDA) has authorized BioRestorative to begin a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain resulting from pain-causing degenerative discs. Currently, BioRestorative Therapies is actively recruiting patients to participate in the Phase 2 study. More information can be found here https://clinicaltrials.gov/ct2/show/NCT04042844?term=brtx&draw=2&rank=1. Another treatment BioRestorative is developing is ThermoStem, which targets obesity and metabolic disorders through the use of brown adipose-derived stem cells to generate new brown fat tissue. This brown fat tissue has been shown to increase metabolic activity and potentially regulate metabolic dysfunction in mice. New Developments Might Promise Better Health BioRestorative Therapies’ leadership is excited about the company’s ability to continue developing its two major technologies that could potentially provide access to multibillion-dollar markets. The company raised $23 million last November 2021 and is funded to prosecute its phase 2 clinical trial targeting chronic lumbar disc disease. Major Catalyst Near Term BioRestorative plans to unveil major safety data for its new therapies within the first quarter of 2023. Company leadership believes this will be a major catalyst for driving growth because positive safety data would provide acceleration to enrollment in and provide major validation for BRTX-100’s Phase 2 clinical trial for lower back pain. BioRestorative also reports that top key opinion leaders (KOLS) are highly engaged in the company’s research and development and are having their clinical sites participate in BioRestorative’s clinical trial. The Company also reports they are oversubscribed in terms of high-quality clinical site selection. With the company’s recent developments, upcoming safety data reveals and involvement of KOLS, BioRestorative is confident that it is heading in a positive direction and is hopeful it will positively impact the lives of millions. BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations ir@biorestorative.com Company Website https://www.biorestorative.com/

September 01, 2022 09:00 AM Eastern Daylight Time

1 ... 210 211 212 213 214 ... 308